ArticleJAMIA open2026
RxReduce: a medication deprescribing agent framework leveraging large language models to optimize proton pump inhibitor use.
Article in JAMIA open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Polypharmacy rates continue to rise which can lead to increased risk of adverse drug events. Deprescribing is essential but time-consuming, requiring extensive clinical note and chart review. We developed RxReduce, a large language model (LLM)-powered framework as a proof of concept that can assist with medication deprescribing. Materials and Methods: RxReduce utilizes LLMs and retrieval-augmented generation (RAG) to evaluate patient data. Focusing on proton pump inhibitors, the system analyzes diagnoses and clinical notes to generate recommendations (Continue, Deprescribe, or Stop). To optimize accuracy, clinical notes were preprocessed into summaries before RAG retrieval. Results: The optimized system achieved an F1 score of 0.84, significantly outperforming the baseline (0.70). Conclusion: RxReduce demonstrates the viability of artificial intelligence-assisted deprescribing. By extracting key contextual insights, the framework reduces clinician burden and can be adapted for various medication classes to improve patient safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.